dinutuximab tradename unituxin dinutuximab beta tradename qarziba monoclonal antibodies used secondline treatment children highrisk neuroblastoma antibody made mouse human components targets glycolipid expressed neuroblastoma cells normal cells neuroectodermal origin including central nervous system peripheral nerves differ dinutuximab manufactured using mouse cells dinutuximab beta manufactured using hamster cells dosing regime differs dinutuximab given combination granulocytemacrophage colony stimulating factor gmcsf acid ra dinutuximab beta given alone cause severe side effects including severe pain must controlled morphine high risk infusion reaction must controlled antihistamines antiinflammatory drugs work binding neurons causing bodys immune system destroy dinutuximab received marketing approval us european union march marketing approval withdrawn dinutuximab beta received marketing approval europe antibody originally called discovered group university california san diego led alice yu antibody several others brought clinical trials funded national cancer institute dinutuximab used postconsolidation therapy children highrisk neuroblastoma combination granulocytemacrophage colonystimulating factor acid given patients completed induction therapy consolidation therapy autologous bone marrow transplant external beam radiation therapy part standardofcare therapy newlydiagnosed highrisk neuroblastoma given intravenous infusion ten twenty hours four days also used secondline relapsedrefractory neuroblastoma combination chemotherapy gmcsf dinutuximab beta also used second line treatment children highrisk neuroblastoma tested used longer slower dosing regime given although may combined stronger immune response morphine administered prior two hours infusion dinutuximab dinutuximab beta manage severe pain drug causes antihistamine antiinflammatory also given manage infusion women pregnant might become pregnant take dinutuximab dinutuximab beta likely cause harm us label dinutuximab carries black box warnings lifethreatening infusion reactions neurotoxicity causes severe neuropathic pain cause severe sensory neuropathy severe peripheral motor dinutuximab beta also adverse children taking drugs experienced pain fever hives vomiting diarrhea bone marrow suppression causing loss platelets red blood cells white blood cells albumin hypotension electrolyte imbalance including low sodium potassium calcium elevated transaminases infusion reactions capillary leak common adverse effects include retention urine weeks months receiving drugs protein urine blurred vision dilated pupils infections edema high blood pressure bleeding wont stop tachycardia weight dinutuximab dinutuximab beta work binding glycolipid found cells originating neuroectoderm prenatal development including neurons central nervous system peripheral nervous system neuroblastoma cells well dinutuximab binds cell cell destroyed via cellmediated cytotoxicity complementdependent clinical trials dinutuximab maximum plasma concentration mcgml mean steady state volume distribution l clearance rate lday average halflife chimeric monoclonal antibody variable heavy light chain regions come mouse human constant region heavy chain light chain version dinutuximab made united therapeutics marketed brand name unituxin manufactured via industrial fermentation using murine myeloma cell line version marketed eusa apeiron called generically dinutuximab beta marketed brand name isquette manufactured chinese hamster ovary dinutuximab originally called discovered group university california san diego led alice yu antibody several others brought clinical trials funded national cancer nci manufactured mabs phase iii combination gmcsf halted due clear efficacy results published company offered time get fda approval commercialize drug nci kept manufacturing making available compassionate nci signed agreement united therapeutics company took manufacturing would bring drug meantime europe oncologists patient advocates wanted drug available europe made efforts obtain cell line used make united therapeutics originating lab nci efforts failed reached group memorial sloan kettering generated mab making msk administration patients didnt work lab childrens cancer research institute vienna collaboration network european oncologists developed mab made cho cells phase iii clinical trials institute licensed rights apeiron local biotech fda approved united therapeutics application march european medicines united therapeutics withdrew european marketing authorization said trouble making enough drug sell october apeiron licensed rights uk biotech company may apeiron eusa obtained ema approval market called dinutuximab httpsenwikipediaorgwikidinutuximab